Vivos Therapeutics Inc (NASDAQ: VVOS) will release its second quarter 2026 financial results after market close on Friday, August 14, 2026. The medical device company, which focuses on treating obstructive sleep apnea (OSA), will also hold a conference call at 5:00 pm Eastern Time to discuss the results and provide operational updates.

Management plans to address strategic collaborations and their anticipated effect on near-term revenue growth and cash burn during the call. Investors can access the live webcast on the company’s website or via telephone dial-in.

Conference Call Details

The conference call is scheduled for 5:00 pm Eastern Time. Participants can join via the following methods:

• US Dial-in: (800) 717-1738
• International Dial-in: (646) 307-1865
• Webcast: Available on Vivos’ investor relations page

A replay of the call will be available shortly after the event until Friday, August 28, 2026. The passcode for the replay is 1174558.

About Vivos Therapeutics

Vivos Therapeutics develops and commercializes diagnostic and treatment modalities for patients with obstructive sleep apnea and other sleep-related breathing disorders. Its Complete Airway Repositioning and Expansion (CARE) devices are FDA-cleared for treating severe OSA in adults and moderate-to-severe OSA in children aged 6 to 17.

The company’s approach, known as The Vivos Method, offers a nonsurgical, noninvasive, and nonpharmaceutical solution targeting underlying physiological deficiencies associated with OSA.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced an expanded strategic partnership with Greenway Health on Aug. 11, 2026, to deploy Greenway’s Novare AI platform across its clinical operations. The collaboration aims to generate up to $9.1 million in potential annual value and save approximately $1.8 million in labor costs at Sleep Centers of Nevada (SCN). This operational enhancement is designed to create meaningful operating leverage as the company scales its healthcare services business.

The partnership focuses on implementing Greenway’s AI-by-design Novare platform to automate workflows and improve patient capacity. Implementation has already commenced at SCN, a key component of Vivos’ growing clinical network. The company expects these changes to reduce administrative workload while increasing the volume of patient visits, thereby enhancing overall operational efficiency.

Financial Impact and Operational Metrics

Greenway’s analysis of operational data from SCN indicates significant potential for value creation through automation. The projected financial benefits are split between increased patient capacity and revenue-cycle improvements.

In addition to the direct value creation from patient capacity and revenue cycles, Vivos estimates additional savings of up to $1.8 million annually. These savings stem from the recovery of an estimated 46,000+ employee hours per year. The combination of incremental revenue capacity and reduced administrative burden is expected to drive efficiency gains.

Strategic Implications

The deployment of the Novare platform represents a shift toward AI-enabled automation in Vivos’ healthcare services segment. By recovering nearly 30,000 additional patient visit capacities annually, the company can address demand without proportional increases in headcount. This approach aligns with broader industry trends leveraging artificial intelligence to optimize healthcare delivery and reduce operational costs.

What the Numbers Show

The financial projections highlight a dual benefit structure: top-line growth through increased patient capacity and bottom-line improvement via labor cost savings. The $9.0 million in potential annual value from capacity and revenue-cycle improvements is distinct from the $1.8 million in labor savings, suggesting that the automation addresses both service volume constraints and administrative inefficiencies. The recovery of 46,000+ labor hours underscores the significant administrative burden currently present in operations, which the Novare platform aims to alleviate.